Literature DB >> 17171647

Suppression of growth factor expression and human vascular smooth muscle cell growth by small interfering RNA targeting EGR-1.

Roger G Fahmy1, Levon M Khachigian.   

Abstract

Smooth muscle cell (SMC) proliferation and migration are key processes that occur in the reparative response to injury after percutaneous coronary intervention and in failed bypass grafts for the treatment of atherosclerosis. In the present study, we generated novel synthetic small interfering RNA (siRNA) molecules targeting the coding region of human early growth response-1 (EGR-1) mRNA that attenuate the expression of EGR-1 and that of fibroblast growth factor-2 (FGF-2) and granulocyte-colony stimulating factor (G-CSF). These agents suppressed SMC proliferation in a dose-dependent and non-toxic manner and blocked SMC regrowth from the wound edge following mechanical injury in vitro. In contrast, the scrambled counterpart did not inhibit SMC proliferation, EGR-1 protein expression or SMC regrowth after injury. These findings demonstrate that EGR-1 siRNA can serve as inhibitors of SMC proliferation and wound repair suggesting that these agents may potentially be useful in the control of vascular proliferative disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17171647     DOI: 10.1002/jcb.21145

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  13 in total

1.  Serum and glucocorticoid-regulated kinase 1 promotes vascular smooth muscle cell proliferation via regulation of β-catenin dynamics.

Authors:  Wei Zhong; Babayewa Oguljahan; Yan Xiao; James Nelson; Liliana Hernandez; Minerva Garcia-Barrio; Sharon C Francis
Journal:  Cell Signal       Date:  2014-08-22       Impact factor: 4.315

Review 2.  DNAzymes and cardiovascular disease.

Authors:  V L Benson; L M Khachigian; H C Lowe
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

3.  Egr-1 expression during neointimal development in flow-associated pulmonary hypertension.

Authors:  Michael G Dickinson; Beatrijs Bartelds; Grietje Molema; Marinus A Borgdorff; Bibiche Boersma; Janny Takens; Michel Weij; Pieter Wichers; Hannie Sietsma; Rolf M F Berger
Journal:  Am J Pathol       Date:  2011-09-13       Impact factor: 4.307

4.  Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events.

Authors:  Jai-Hyun Kim; Dong Soon Choi; Ok-Hee Lee; Seung-Hyun Oh; Scott M Lippman; Ho-Young Lee
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

5.  FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway.

Authors:  Filippos Kottakis; Christos Polytarchou; Parthena Foltopoulou; Ioannis Sanidas; Sotirios C Kampranis; Philip N Tsichlis
Journal:  Mol Cell       Date:  2011-07-22       Impact factor: 17.970

6.  Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1 induction in human vascular smooth muscle cells.

Authors:  Brian D Lamon; Barbara D Summers; Antonio M Gotto; David P Hajjar
Journal:  Eur J Pharmacol       Date:  2009-01-14       Impact factor: 4.432

7.  Egr-1 upregulates OPN through direct binding to its promoter and OPN upregulates Egr-1 via the ERK pathway.

Authors:  Qi-Feng Liu; Hong-Wei Yu; Gui-Nan Liu
Journal:  Mol Cell Biochem       Date:  2009-06-26       Impact factor: 3.396

8.  Live in vivo imaging of Egr-1 promoter activity during neonatal development, liver regeneration and wound healing.

Authors:  Philipp Dussmann; Judith I Pagel; Sabina Vogel; Terese Magnusson; Rene Zimmermann; Ernst Wagner; Wolfgang Schaper; Manfred Ogris; Elisabeth Deindl
Journal:  BMC Dev Biol       Date:  2011-05-20       Impact factor: 1.978

9.  Association of SNPs in EGR3 and ARC with Schizophrenia Supports a Biological Pathway for Schizophrenia Risk.

Authors:  Matthew J Huentelman; Leela Muppana; Jason J Corneveaux; Valentin Dinu; Jeremy J Pruzin; Rebecca Reiman; Cassie N Borish; Matt De Both; Amber Ahmed; Alexandre Todorov; C Robert Cloninger; Rui Zhang; Jie Ma; Amelia L Gallitano
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

10.  Inhibition of Egr1 expression underlies the anti-mitogenic effects of cAMP in vascular smooth muscle cells.

Authors:  Tomomi E Kimura; Aparna Duggirala; Charles C T Hindmarch; Richard C Hewer; Mei-Zhen Cui; Andrew C Newby; Mark Bond
Journal:  J Mol Cell Cardiol       Date:  2014-02-15       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.